Times Square Capital Management, LLC Intra Cellular Therapies, Inc. Transaction History
Times Square Capital Management, LLC
- $6.49 Billion
- Q3 2024
A detailed history of Times Square Capital Management, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Times Square Capital Management, LLC holds 438,083 shares of ITCI stock, worth $36.6 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
438,083
Previous 411,483
6.46%
Holding current value
$36.6 Million
Previous $28.2 Million
13.66%
% of portfolio
0.49%
Previous 0.45%
Shares
17 transactions
Others Institutions Holding ITCI
# of Institutions
377Shares Held
84.1MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$803 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$528 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$441 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$321 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$255 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $7.88B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...